US2012017806A1PendingUtilityA1
Ophthalmic and Contact Lens Solutions Using Low Molecular Weight Amines
Est. expiryNov 4, 2020(expired)· nominal 20-yr term from priority
Inventors:Francis X. Smith
A01N 47/44A61L 12/12A45C 11/005A01N 59/00A61L 12/143A61L 2/18A01N 37/44C09D 7/63A01N 33/12C09D 5/00A01N 43/50G02B 1/18A61L 12/086A01N 43/38A61L 12/145A61L 12/124A61L 12/142
68
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to a lens care solution comprising: 0.001 to about 5 weight percent of a low molecular weight amine of the general formula: Where R 1 , R 2 , R 3 and R 4 are —H or low molecular weight radicals, and R 5 is a low molecular weight radical, or salt thereof; an effective amount of tonicity agent; and the balance water.
Claims
exact text as granted — not AI-modified1 . An ophthalmic solution comprising:
0.001 to about 5 weight percent of a low molecular weight amine of the general formula:
where R 1 , R 2 , R 3 , and R 4 are —H or low molecular weight radicals, and R 5 is a low molecular weight radical, or salts thereof; an effective amount of biologically compatible buffer to maintain the pH of the solution between 5.5 and 8.5 pH; and
the balance water.
2 . The ophthalmic solution of claim 1 that further comprises an effective amount of a tonicity agent.
3 . The ophthalmic solution of claim 1 where the amine is Betaine.
4 . The ophthalmic solution of claim 1 where the amine is Bicine (N,N-Bis(2-hydroxyethyl)-glycline).
5 . The ophthalmic solution of claim 1 where the amine is Bis-Tris(Bis-(2-hydroxyethyl)imino-tris(hydroxymethyl)methane.
6 . The ophthalmic solution of claim 1 where the amine is Choline.
7 . The ophthalmic solution of claim 1 where the amine is Carnitine.
8 . The ophthalmic solution of claim 1 where the amine is Creatine.
9 . The ophthalmic solution of claim 1 where the amine is Creatinine.
10 . The ophthalmic solution of claim 1 where the amine is Diisopropylamine.
11 . The ophthalmic solution of claim 1 where the amine is Diethanolamine.
12 . The ophthalmic solution of claim 1 where the amine is Dimethyl Aspartic Acid.
13 . The ophthalmic solution of claim 1 where the amine is Dimethyl glutamate.
14 . The ophthalmic solution of claim 1 where the amine is Methyl Aspartate.
15 . The ophthalmic solution of claim 1 where the amine is Methylethanolamine.
16 . The ophthalmic solution of claim 1 where the amine is Hydroxymethyl Glycinate.
17 . The ophthalmic solution of claim 1 where the amine is Triethylamine.
18 . The ophthalmic solution of claim 1 where the amine is Triethanolamine.
19 . The ophthalmic solution of claim 1 where the amine is Tricine (N-tris(hydroxymethyl)methyl glycine).
20 . The ophthalmic solution of claim 1 where the amine is Triisopropanolamine.
21 . The ophthalmic solution of claim 1 wherein R 1 is chosen from the group of radicals presented by the following formulae:
D,L Side Chains
R1
—H
—CH 3
—CH 2 —COO −
—CH 2 CH 2 —COO −
—CH 2 CH 2 OH
—CH 2 CH(CH 3 ) 2
—CH(CH 3 ) 2
—CH 2 OH
—CH 2 —SH
—CH 2 CH 2 —S—CH 3
22 . The ophthalmic solution of claim 1 wherein R 2 is chosen from the group of radicals presented by the following formulae:
23 . The ophthalmic solution of claim 1 wherein R 3 is chosen from the group of radicals presented by the following formulae:
24 . The ophthalmic solution of claim 1 wherein R 4 is chosen from the group of radicals presented by the following formulae:
25 . The ophthalmic solution of claim 1 wherein R 5 is chosen from the group of radicals presented by the following formulae:
26 . An ophthalmic product comprising:
at least one contact lens; a contact lens container; and sufficient contact lens solution to wet said contact lens where said solution comprises: 0.001 to about 5 weight percent of a low molecular weight amine of the general formula:
where R 1 , R 2 , R 3 and R 4 are —H or low molecular weight radicals, and R 5 is a low molecular weight radical, or salts thereof; and the balance water.
27 . The ophthalmic product of claim 26 where R 1 , R 2 , R 3 , R 4 and R 5 are chosen from the following groups or salts thereof;
D,L Side Chains
R1
—H
—CH 3
—CH 2 —COO −
—CH 2 CH 2 —COO −
—CH 2 CH 2 OH
—CH 2 CH(CH 3 ) 2
—CH(CH 3 ) 2
—CH 2 OH
—CH 2 —SH
—CH 2 CH 2 —S—CH 3
R2
—COO −
—CH 2 OH
—CH 3
R3, R4, R5
—H
—CH 3
—CH 2 CH 3
—CH 2 CH 2 CH 3
—CH(CH 3 ) 2
—CH 2 OH
—CH 2 CH 2 OH
28 . A method for treating a contact lens in order to decrease its affinity to protein deposition which comprises the step of:
soaking a contact lens in an aqueous solution comprising 0.001 to 5 weight percent a low molecular weight amine of the general formula:
where R 3 and R 4 are low molecular weight radicals; and R 1 and R 2 are —H or low molecular weight radicals; and where R 1 , R 2 , R 3 , R 4 and R 5 can be chosen from the following groups or salts thereof;
D,L Side Chains
R1
—H
—CH 3
—CH 2 —COO −
—CH 2 CH 2 —COO −
—CH 2 CH 2 OH
—CH 2 CH(CH 3 ) 2
—CH(CH 3 ) 2
—CH 2 OH
—CH 2 —SH
—CH 2 CH 2 —S—CH 3
R2
—COO −
—CH 2 OH
—CH 3
R3, R4, R5
—H
—CH 3
—CH 2 CH 3
—CH 2 CH 2 CH 3
—CH(CH 3 ) 2
—CH 2 OH
—CH 2 CH 2 OHCited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.